Kilitch Drugs Approves ₹50 Crore Rights Issue at ₹357/share; Board Sets July 15 as Record Date
By Shishta Dutta | Published at: Jul 10, 2025 09:30 AM IST
Mumbai, July 10, 2025 — Kilitch Drugs (India) Ltd (NSE: KILITCH | BSE: 524500) has approved a ₹49.95 crore rights issue to raise capital through the issuance of 13,98,463 fully paid-up equity shares at ₹357 apiece, including a premium of ₹347 per share. The face value of each share is ₹10.
The board cleared the proposal in its meeting held on July 9, 2025, following in-principle approvals from NSE and BSE earlier this week. The issue price is fully payable at the time of application, and shareholders as on the record date, Tuesday, July 15, 2025, will be eligible to subscribe.
Rights Issue Details
- The company has announced a rights issue of fully paid-up equity shares.
- A total of 13,98,463 equity shares will be offered through this issue.
- The issue price is set at ₹357 per share, comprising a ₹10 face value and a ₹347 premium.
- 100% of the issue price is payable at the time of application.
- The record date to determine shareholder eligibility is July 15, 2025.
- Shareholders will be entitled to 2 equity shares for every 23 shares held as on the record date.
- The rights issue period will be announced separately.
- The Rights Entitlement ISIN is yet to be disclosed.
| Particulars | Details |
|---|---|
| Type of Issue | Rights Issue of Fully Paid-up Equity Shares |
| Number of Shares Offered | 13,98,463 equity shares |
| Face Value | ₹10 per share |
| Issue Price | ₹357 per share (including ₹347 premium) |
| Terms of Payment | 100% payable on application |
| Record Date | July 15, 2025 |
| Entitlement Ratio | 2 shares for every 23 held |
| Rights Issue Period | To be announced separately |
| Rights Entitlement ISIN | To be announced separately |
Share Capital Positioning
| Particulars | Equity Shares Count |
|---|---|
| Pre-Issue Equity Shares | 1,60,82,319 |
| Post-Issue Equity Shares (Full Subscr.) | 1,74,80,782 |
The rights entitlement ratio is set at 2 shares for every 23 held, with the option to renounce, ensuring existing shareholders have the opportunity to maintain or adjust their stake based on investment outlook.
Kilitch Drugs (India) Stock Performance
Kilitch Drugs (India) shares closed at ₹420, which is a 0.53% dip on July 9, 2025. Kilitch Drugs (India) shares have gained 21% in the last year, up 2% in the year-to-date, and down 7.25% in the previous month.
About Kilitch Drugs (India)
Kilitch Drugs (India) Ltd is a WHO-GMP and ISO-certified pharmaceutical manufacturer. The company is listed on both BSE and NSE. With operations spanning domestic and international markets, the company specialises in injectable products and oral formulations. Thereby, the company serves both private and institutional clients.
For eligibility and subscription details, investors are advised to monitor updates on the NSE and BSE platforms.
REF: https://nsearchives.nseindia.com/corporate/KILITCH_09072025190723_OutcomeOfBoardMetting09072025.pdf
Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.
If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.
Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations
